2020 Q1 Form 10-Q Financial Statement

#000143774920010599 Filed on May 13, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q1 2018 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.020M $810.0K $380.0K
YoY Change 25.93% 55.77% -50.0%
% of Gross Profit
Research & Development $1.349M $2.607M $1.740M
YoY Change -48.25% 229.58% 167.69%
% of Gross Profit
Depreciation & Amortization $6.000K $6.000K $10.00K
YoY Change 0.0% 50.0%
% of Gross Profit
Operating Expenses $1.349M $3.421M $2.120M
YoY Change -60.57% 161.94% 50.35%
Operating Profit -$2.404M -$3.421M
YoY Change -29.73% 161.94%
Interest Expense $0.00 -$10.00K
YoY Change -100.0% -106.67%
% of Operating Profit
Other Income/Expense, Net -$12.00K -$178.0K $180.0K
YoY Change -93.26% -127.09% -28.0%
Pretax Income -$2.416M -$3.243M -$1.960M
YoY Change -25.5% 399.69% 94.06%
Income Tax $9.000K $9.000K $10.00K
% Of Pretax Income
Net Earnings -$2.425M -$3.252M -$1.960M
YoY Change -25.43% 400.31% 100.0%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$185.4K -$271.7K -$219.2K
COMMON SHARES
Basic Shares Outstanding 14.14M 11.96M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2019 Q1 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.60M $13.76M $16.82M
YoY Change -8.42% 104.75% 1145.93%
Cash & Equivalents $3.300M $2.759M $16.82M
Short-Term Investments $9.300M $11.00M
Other Short-Term Assets $540.0K $300.0K $370.0K
YoY Change 80.0% 500.0% 516.67%
Inventory
Prepaid Expenses $369.0K
Receivables $985.0K $929.0K $780.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $14.17M $14.94M $17.97M
YoY Change -5.21% 97.41% 1102.95%
LONG-TERM ASSETS
Property, Plant & Equipment $60.00K $90.00K $96.00K
YoY Change -33.33% 28.57% 159.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $270.0K $270.0K
YoY Change 0.0% 0.0%
Total Long-Term Assets $200.0K $550.0K $367.0K
YoY Change -63.64% 66.67% 19.16%
TOTAL ASSETS
Total Short-Term Assets $14.17M $14.94M $17.97M
Total Long-Term Assets $200.0K $550.0K $367.0K
Total Assets $14.37M $15.49M $18.34M
YoY Change -7.29% 96.13% 917.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $444.0K $685.0K $483.0K
YoY Change -35.18% 7.03% -47.5%
Accrued Expenses $435.0K $686.0K $808.0K
YoY Change -36.59% 67.32%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $10.00K $10.00K $10.00K
YoY Change 0.0%
Total Short-Term Liabilities $935.0K $1.425M $1.296M
YoY Change -34.39% 28.38% 29.21%
LONG-TERM LIABILITIES
Long-Term Debt $10.00K $20.00K $20.00K
YoY Change -50.0%
Other Long-Term Liabilities $100.0K $150.0K
YoY Change -33.33% -92.72%
Total Long-Term Liabilities $107.0K $163.0K $18.00K
YoY Change -34.36% -92.09%
TOTAL LIABILITIES
Total Short-Term Liabilities $935.0K $1.425M $1.296M
Total Long-Term Liabilities $107.0K $163.0K $18.00K
Total Liabilities $1.042M $1.588M $1.314M
YoY Change -34.38% -49.91% 31.01%
SHAREHOLDERS EQUITY
Retained Earnings -$59.04M -$49.22M -$45.97M
YoY Change 19.96% 14.25%
Common Stock $0.00 $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $13.32M $13.91M $17.03M
YoY Change
Total Liabilities & Shareholders Equity $14.37M $15.49M $18.34M
YoY Change -7.29% 96.13% 917.7%

Cashflow Statement

Concept 2020 Q1 2019 Q1 2018 Q4
OPERATING ACTIVITIES
Net Income -$2.425M -$3.252M -$1.960M
YoY Change -25.43% 400.31% 100.0%
Depreciation, Depletion And Amortization $6.000K $6.000K $10.00K
YoY Change 0.0% 50.0%
Cash From Operating Activities -$2.978M -$3.134M -$1.900M
YoY Change -4.98% 235.19% 95.88%
INVESTING ACTIVITIES
Capital Expenditures $2.000K $10.00K
YoY Change -200.0%
Acquisitions
YoY Change
Other Investing Activities -$5.300M -$10.93M
YoY Change -51.51%
Cash From Investing Activities -$5.301M -$10.93M $10.00K
YoY Change -51.49% 34050.0% -200.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $8.500M $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.696M -2.000K 14.82M
YoY Change -384900.0% -100.03% 856.13%
NET CHANGE
Cash From Operating Activities -2.978M -3.134M -1.900M
Cash From Investing Activities -5.301M -10.93M 10.00K
Cash From Financing Activities 7.696M -2.000K 14.82M
Net Change In Cash -583.0K -14.06M 12.93M
YoY Change -95.85% -362.54% 2168.42%
FREE CASH FLOW
Cash From Operating Activities -$2.978M -$3.134M -$1.900M
Capital Expenditures $2.000K $10.00K
Free Cash Flow -$2.980M -$3.134M -$1.910M
YoY Change -4.91% 224.1% 98.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 dmac Accrued Clinical Study Costs Current
AccruedClinicalStudyCostsCurrent
295000
CY2019Q4 dmac Accrued Clinical Study Costs Current
AccruedClinicalStudyCostsCurrent
433000
CY2020Q1 dmac Accrued Research And Professional Fees Current
AccruedResearchAndProfessionalFeesCurrent
49000
CY2019Q4 dmac Accrued Research And Professional Fees Current
AccruedResearchAndProfessionalFeesCurrent
172000
CY2020Q1 dmac Accrued Taxes And Other Liabilities Current
AccruedTaxesAndOtherLiabilitiesCurrent
18000
CY2019Q4 dmac Accrued Taxes And Other Liabilities Current
AccruedTaxesAndOtherLiabilitiesCurrent
52000
CY2020Q1 dmac Income From Governmental Assistance
IncomeFromGovernmentalAssistance
115000
CY2019Q1 dmac Income From Governmental Assistance
IncomeFromGovernmentalAssistance
174000
CY2020Q1 dmac Noncash Lease Expense
NoncashLeaseExpense
13000
CY2019Q1 dmac Noncash Lease Expense
NoncashLeaseExpense
12000
CY2020Q1 dmac Proceeds From Issuance Of Common Stock Net
ProceedsFromIssuanceOfCommonStockNet
7700000
CY2020Q1 dmac Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
908000
CY2019Q4 dmac Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
793000
CY2020Q1 dmac Working Capital
WorkingCapital
13200000
CY2020Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
435000
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1076000
CY2020Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
444000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
182000
CY2020Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
985000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
823000
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
435000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1076000
CY2020Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
49000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
43000
CY2020Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
42000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2000
CY2020Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
72323000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
64232000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
393000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
130000
CY2020Q1 us-gaap Assets
Assets
14365000
CY2019Q4 us-gaap Assets
Assets
9053000
CY2020Q1 us-gaap Assets Current
AssetsCurrent
14165000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
8836000
CY2020Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
200000
CY2019Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
217000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3883000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16823000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3300000
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2759000
CY2020Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-583000
CY2019Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-14064000
CY2020Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
3300000
CY2020Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2821192
CY2020Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2019Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3243000
CY2019Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2020Q1 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2019 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14139074
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12006874
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14139074
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12006874
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2385000
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3249000
CY2020Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Concentration of credit risk</div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains its cash balances primarily with <div style="display: inline; font-style: italic; font: inherit;">two</div> financial institutions. These balances generally exceed federally insured limits. The Company has <div style="display: inline; font-style: italic; font: inherit;">not</div> experienced any losses in such accounts and believes it is <div style="display: inline; font-style: italic; font: inherit;">not</div> exposed to any significant credit risk in cash and cash equivalents. The Company believes that the credit risk related to marketable securities is limited due to the adherence to an investment policy focused on the preservation of principal.</div></div></div></div></div></div></div></div>
CY2020Q1 us-gaap Deposits Assets Current
DepositsAssetsCurrent
195000
CY2019Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
88000
CY2020Q1 us-gaap Depreciation
Depreciation
6000
CY2019Q1 us-gaap Depreciation
Depreciation
6000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2020Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
73000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
419000
CY2020Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
6000
CY2019Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
6000
CY2020Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
11000
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
13000
CY2020Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
2000
CY2019Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
2000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1023000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
814000
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2416000
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9000
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9000
CY2020Q1 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
38000
CY2019Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
13000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
262000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
201000
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
162000
CY2019Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
150000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-654000
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-127000
CY2020Q1 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
107000
CY2019Q1 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
CY2020Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
290000
CY2019Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-72000
CY2020Q1 us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
14000
CY2019Q1 us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
26000
CY2020Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.09
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
163000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
46000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
68000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
49000
CY2020Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
17000
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14365000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9053000
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
935000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1318000
CY2020Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
107000
CY2019Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
118000
CY2020Q1 us-gaap Marketable Securities
MarketableSecurities
9300000
CY2020Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
9348000
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
3995000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3421000
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
16000
CY2020Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
146000
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
50000
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-178000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2404000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7696000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5301000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10928000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2978000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3134000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2425000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-3252000
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
12000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
54000
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
96000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
105000
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
140000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
153000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
40000
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-127000
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4000
CY2020Q1 us-gaap Other Receivables
OtherReceivables
39000
CY2019Q4 us-gaap Other Receivables
OtherReceivables
17000
CY2020Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
8799000
CY2019Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
10928000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
CY2020Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
337000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
47000
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8500000
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7682000
CY2019Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
CY2020Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
3500000
CY2019Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
16000
CY2019Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
CY2020Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
109000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
107000
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
60000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
64000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1381000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2607000
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-59042000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-56617000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
393000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
130000
CY2020Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
677566
CY2020Q1 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
1181309
CY2020Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P7Y109D
CY2020Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
5.21
CY2020Q1 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P8Y
CY2020Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
4
CY2020Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
393000
CY2019Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
130000
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2125000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7682000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
13323000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
7617000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
17025000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
13906000
CY2020Q1 us-gaap Variable Lease Cost
VariableLeaseCost
13000
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13107725
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11956874

Files In Submission

Name View Source Status
0001437749-20-010599-index-headers.html Edgar Link pending
0001437749-20-010599-index.html Edgar Link pending
0001437749-20-010599.txt Edgar Link pending
0001437749-20-010599-xbrl.zip Edgar Link pending
diagraph.jpg Edgar Link pending
dmac-20200331.xml Edgar Link completed
dmac-20200331.xsd Edgar Link pending
dmac-20200331_cal.xml Edgar Link unprocessable
dmac-20200331_def.xml Edgar Link unprocessable
dmac-20200331_lab.xml Edgar Link unprocessable
dmac-20200331_pre.xml Edgar Link unprocessable
dmtp20200331_10q.htm Edgar Link pending
ex_184772.htm Edgar Link pending
ex_184813.htm Edgar Link pending
ex_184814.htm Edgar Link pending
ex_184817.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending